Department of Oncology, First Affiliated Hospital, Cancer Institute, Henan University of Science and Technology, Luoyang 471003, Henan Province, China.
World J Gastroenterol. 2011 Dec 21;17(47):5221-6. doi: 10.3748/wjg.v17.i47.5221.
To evaluate the effects and safety of combination chemotherapy with oxaliplatin (L-OHP) and S-1 (SOX regimen) in older patients with advanced gastric cardiac adenocarcinoma (GCA).
Seventy patients with advanced GCA were classified according to age into an older group (≥ 75 years) and a control group (< 75 years). The SOX regimen was administered to the two groups as follows: S-1 (40 mg/m² po bid) on days 1 to 14 followed by a 7-d off period, plus L-OHP (65 mg/m² iv) for 2 h on days 1 and 8 of a 21-d cycle. This regimen was repeated for four to six cycles. Response and swallow statuses were evaluated after two cycles (6 wk). Effects and toxicity were evaluated four weeks after chemotherapy was completed.
The response rate was 65.6% (21/32) in the older group and 68.4% (26/38) in the control group (χ² = 0.062 and P = 0.804). Improvement in swallowing was 78.1% (25/32) in the older group and 76.3% (29/38) in the control group (χ² = 0.032 and P = 0.857). Efficacy was 68.8% (22/32) in the older group and 65.8% (25/38) in the control group (χ² = 0.069 and P = 0.793). Toxicities were reversible and similar in both groups (P > 0.05).
The SOX regimen is an effective, safe and well-tolerated regimen for older patients with advanced GCA.
评估奥沙利铂（L-OHP）和 S-1（SOX 方案）联合化疗治疗高龄晚期胃贲门腺癌（GCA）患者的疗效和安全性。
70 例晚期 GCA 患者按年龄分为高龄组（≥75 岁）和对照组（＜75 岁）。两组均采用 SOX 方案治疗：S-1（40mg/m² po bid）第 1-14 天，停药 7 天，L-OHP（65mg/m² iv）2h，第 1 天和第 8 天，21 天为 1 个周期，共 4-6 个周期。两个周期（6 周）后评估反应和吞咽状况。化疗结束后 4 周评价疗效和毒性。
高龄组有效率为 65.6%（21/32），对照组为 68.4%（26/38）（χ²=0.062，P=0.804）。高龄组吞咽改善率为 78.1%（25/32），对照组为 76.3%（29/38）（χ²=0.032，P=0.857）。高龄组疾病控制率为 68.8%（22/32），对照组为 65.8%（25/38）（χ²=0.069，P=0.793）。两组不良反应均为可逆性，且相似（P＞0.05）。
SOX 方案是治疗高龄晚期 GCA 患者安全有效的方案。
